Quetiapine Fumarate Tablet
Product Images NDC 68071-3940

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Quetiapine Fumarate (NDC 68071-3940). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (35b3883e Bd69 43d5 8f5a 254dd92cd528 1584 1)

Quetiapine fumarate 300 mg oral tablets, packaged in a white and blue carton from NuCare Pharmaceuticals, Inc. The front panel features the product name, strength, dosage form, and labeler information. The package appears to contain multiple tablets, as depicted by the blister pack image on the label.*

FDA Label Image

Pdp (68071 3940 6)

Label for Quetiapine fumarate 300 mg tablets, oral dosage form, by NuCare Pharmaceuticals, Inc. It contains 60 film-coated tablets equivalent to Quetiapine 300 mg each. The label includes storage instructions, manufacturer and packager details, patient instructions, and drug identification with NDC 68071-3940.*

FDA Label Image

Image (9fb56acd 2611 4c7d B63f 1de0c57383ea 1628 1)

Quetiapine fumarate 300 mg oral tablets in a blister pack from NuCare Pharmaceuticals, Inc. The blister pack contains 14 round tablets arranged in two columns of seven. The packaging is white with black printed text, showing the product name and strength.*

FDA Label Image

Molecular Structure (A644051f 21f4 4c76 9ed2 E96417d77df9 01)

Chemical structure diagram of quetiapine fumarate, showing the molecular arrangement of two quetiapine molecules and one fumarate ion with labeled atoms and bonds.*

FDA Label Image

Figure 1 (A644051f 21f4 4c76 9ed2 E96417d77df9 02)

A line graph depicting the proportion of patients with relapse (%) over time (weeks). Two groups are compared: QTP+LI/VAL and PLA+LI/VAL, showing relapse rates over approximately 100 weeks. The QTP+LI/VAL group has a lower relapse proportion compared to the PLA+LI/VAL group throughout the study period.*

FDA Label Image

Figure 2 (A644051f 21f4 4c76 9ed2 E96417d77df9 03)

A line graph illustrating the proportion of patients with relapse (%) over time in weeks, comparing two groups labeled QTP+LI/VAL (dashed line) and PLA+LI/VAL (solid line). The graph shows increasing relapse rates over 100 weeks, with the PLA+LI/VAL group consistently having higher relapse proportions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.